AIP
PRLD icon

Ameritas Investment Partners’s Prelude Therapeutics PRLD Stock Holding History

Ameritas Investment Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
+2,520
New +$11K ﹤0.01% 2932
2025
Q2 		– Sell
-819
Closed -$629 – 3307
2025
Q1 		$629 Hold
819
– – ﹤0.01% 3119
2024
Q4 		$1.04K Hold
819
– – ﹤0.01% 3118
2024
Q3 		$1.7K Hold
819
– – ﹤0.01% 3103
2024
Q2 		$3.12K Hold
819
– – ﹤0.01% 3072
2024
Q1 		$3.88K Hold
819
– – ﹤0.01% 2980
2023
Q4 		$3.5K Hold
819
– – ﹤0.01% 3016
2023
Q3 		$2.53K Hold
819
– – ﹤0.01% 3051
2023
Q2 		$3.69K Buy
+819
New +$4.89K ﹤0.01% 3062
2022
Q2 		– Sell
-769
Closed -$5K – 3198
2022
Q1 		$5K Hold
769
– – ﹤0.01% 2973
2021
Q4 		$10K Hold
769
– – ﹤0.01% 2900
2021
Q3 		$24K Hold
769
– – ﹤0.01% 2603
2021
Q2 		$22K Hold
769
– – ﹤0.01% 2689
2021
Q1 		$33K Hold
769
– – ﹤0.01% 2319
2020
Q4 		$55K Buy
+769
New +$38.2K ﹤0.01% 1937

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Ameritas Investment Partners's PRLD Position: Q2 2026 in Review

Ameritas Investment Partners opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 2,520 shares worth $13.4K. The stake represents ﹤0.01% of the portfolio and ranks #2932 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in PRLD as recently as Q1 2025.

Ameritas Investment Partners first reported a position in PRLD in Q4 2020 and has held it in 15 quarters since. The position peaked at $55K in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Ameritas Investment Partners held 2,520 shares of Prelude Therapeutics worth $13.4K as of Q2 2026.
  • Prelude Therapeutics was a new Ameritas Investment Partners position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2932 holding.
  • Ameritas Investment Partners first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Ameritas Investment Partners's Prelude Therapeutics position peaked at $55K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.